Replication attempt: "Effect of BMAP-28 antimicrobial peptides on Leishmania major promastigote and amastigote growth: Role of leishmanolysin in parasite survival"

Reproducibility Initiative

Research output: Contribution to journalArticle

Abstract

This study describes an attempt to replicate experiments from the paper "Effect of BMAP-28 Antimicrobial Peptides on Leishmania major Promastigote and Amastigote Growth: Role of Leishmanolysin in Parasite Survival," which was submitted to the Reproducibility Initiative for independent validation. The cathelicidin bovine myeloid antimicrobial peptide 28 (BMAP-28) and its isomers were previously shown to have potent antiparasitic activity against Leishmania major. We tested the effectiveness of L-BMAP-28 and two of its isomers, the D-amino acid form (D-BMAP-28) and the retro-inverso form (RI-BMAP-28), in both unamidated and amidated forms, as anti-leishmanial agents against Leishmania major promastigotes in vitro. We observed that L-BMAP-28, as well as its D and RI isomers, demonstrate anti-leishmanial activity against L. major promastigotes in vitro. The inhibitory effect was lower than what was seen in the original study. At 2 μM of amidated peptides, the viability was 94%, 36%, and 66% with L-, D- and RI-peptides, versus 57%, 6%, and 18% in the original study.

Original languageEnglish (US)
Article numbere114614
JournalPloS one
Volume9
Issue number12
DOIs
StatePublished - Dec 17 2014

Fingerprint

Leishmania major
amastigotes
promastigotes
antimicrobial peptides
Parasites
parasites
Peptides
cattle
Growth
isomers
Isomers
peptides
Antiparasitic Agents
Leishmania glycoprotein gp63
reproducibility
viability
amino acids
Amino Acids

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Replication attempt : "Effect of BMAP-28 antimicrobial peptides on Leishmania major promastigote and amastigote growth: Role of leishmanolysin in parasite survival". / Reproducibility Initiative.

In: PloS one, Vol. 9, No. 12, e114614, 17.12.2014.

Research output: Contribution to journalArticle

@article{33e523c88bf240aea3d2195b90e52a4b,
title = "Replication attempt: {"}Effect of BMAP-28 antimicrobial peptides on Leishmania major promastigote and amastigote growth: Role of leishmanolysin in parasite survival{"}",
abstract = "This study describes an attempt to replicate experiments from the paper {"}Effect of BMAP-28 Antimicrobial Peptides on Leishmania major Promastigote and Amastigote Growth: Role of Leishmanolysin in Parasite Survival,{"} which was submitted to the Reproducibility Initiative for independent validation. The cathelicidin bovine myeloid antimicrobial peptide 28 (BMAP-28) and its isomers were previously shown to have potent antiparasitic activity against Leishmania major. We tested the effectiveness of L-BMAP-28 and two of its isomers, the D-amino acid form (D-BMAP-28) and the retro-inverso form (RI-BMAP-28), in both unamidated and amidated forms, as anti-leishmanial agents against Leishmania major promastigotes in vitro. We observed that L-BMAP-28, as well as its D and RI isomers, demonstrate anti-leishmanial activity against L. major promastigotes in vitro. The inhibitory effect was lower than what was seen in the original study. At 2 μM of amidated peptides, the viability was 94{\%}, 36{\%}, and 66{\%} with L-, D- and RI-peptides, versus 57{\%}, 6{\%}, and 18{\%} in the original study.",
author = "{Reproducibility Initiative} and Elizabeth Iorns and William Gunn and Jessey Erath and Ana Rodriguez and Jian Zhou and Michael Benzinou and Anita Bandrowski and Bruce Booth and Rathnam Chaguturu and Matthew Ellis and Gaddy Getz and Melissa Haendel and John Ioannidis and Li, {Jian Liang} and Marc Lippman and Bernard Munos and Michael Noble and Brian Nosek and Mark Pegram and Heather Piwowar and George Robertson and Taslimarif Saiyed and Sittampalam, {G. Sitta} and Victoria Stodden and Cathy Tralau-Stewart and Stan Young",
year = "2014",
month = "12",
day = "17",
doi = "10.1371/journal.pone.0114614",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Replication attempt

T2 - "Effect of BMAP-28 antimicrobial peptides on Leishmania major promastigote and amastigote growth: Role of leishmanolysin in parasite survival"

AU - Reproducibility Initiative

AU - Iorns, Elizabeth

AU - Gunn, William

AU - Erath, Jessey

AU - Rodriguez, Ana

AU - Zhou, Jian

AU - Benzinou, Michael

AU - Bandrowski, Anita

AU - Booth, Bruce

AU - Chaguturu, Rathnam

AU - Ellis, Matthew

AU - Getz, Gaddy

AU - Haendel, Melissa

AU - Ioannidis, John

AU - Li, Jian Liang

AU - Lippman, Marc

AU - Munos, Bernard

AU - Noble, Michael

AU - Nosek, Brian

AU - Pegram, Mark

AU - Piwowar, Heather

AU - Robertson, George

AU - Saiyed, Taslimarif

AU - Sittampalam, G. Sitta

AU - Stodden, Victoria

AU - Tralau-Stewart, Cathy

AU - Young, Stan

PY - 2014/12/17

Y1 - 2014/12/17

N2 - This study describes an attempt to replicate experiments from the paper "Effect of BMAP-28 Antimicrobial Peptides on Leishmania major Promastigote and Amastigote Growth: Role of Leishmanolysin in Parasite Survival," which was submitted to the Reproducibility Initiative for independent validation. The cathelicidin bovine myeloid antimicrobial peptide 28 (BMAP-28) and its isomers were previously shown to have potent antiparasitic activity against Leishmania major. We tested the effectiveness of L-BMAP-28 and two of its isomers, the D-amino acid form (D-BMAP-28) and the retro-inverso form (RI-BMAP-28), in both unamidated and amidated forms, as anti-leishmanial agents against Leishmania major promastigotes in vitro. We observed that L-BMAP-28, as well as its D and RI isomers, demonstrate anti-leishmanial activity against L. major promastigotes in vitro. The inhibitory effect was lower than what was seen in the original study. At 2 μM of amidated peptides, the viability was 94%, 36%, and 66% with L-, D- and RI-peptides, versus 57%, 6%, and 18% in the original study.

AB - This study describes an attempt to replicate experiments from the paper "Effect of BMAP-28 Antimicrobial Peptides on Leishmania major Promastigote and Amastigote Growth: Role of Leishmanolysin in Parasite Survival," which was submitted to the Reproducibility Initiative for independent validation. The cathelicidin bovine myeloid antimicrobial peptide 28 (BMAP-28) and its isomers were previously shown to have potent antiparasitic activity against Leishmania major. We tested the effectiveness of L-BMAP-28 and two of its isomers, the D-amino acid form (D-BMAP-28) and the retro-inverso form (RI-BMAP-28), in both unamidated and amidated forms, as anti-leishmanial agents against Leishmania major promastigotes in vitro. We observed that L-BMAP-28, as well as its D and RI isomers, demonstrate anti-leishmanial activity against L. major promastigotes in vitro. The inhibitory effect was lower than what was seen in the original study. At 2 μM of amidated peptides, the viability was 94%, 36%, and 66% with L-, D- and RI-peptides, versus 57%, 6%, and 18% in the original study.

UR - http://www.scopus.com/inward/record.url?scp=84919499008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919499008&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0114614

DO - 10.1371/journal.pone.0114614

M3 - Article

C2 - 25517992

AN - SCOPUS:84919499008

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e114614

ER -